Bio-Works Technologies
Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company
The customer, who has previously used WorkBeads affimAb in several commercial processes, has placed this repeat order as a strong sign of continued confidence in Bio-Works’ products. The order reinforces the ongoing collaboration between the two companies and lays the foundation for a deeper long-term partnership.
WorkBeads affimAb is designed for efficient and selective purification of antibodies and is a highly attractive solution for industrial-scale biopharmaceutical production.
“Receiving a repeat order from a global pharmaceutical leader is a clear validation of our products’ performance in demanding, large-scale processes. It confirms our strategy to be an innovative and trusted partner in biopharmaceutical manufacturing,” says Lone Carlbom, CEO of Bio-Works Technologies AB.
This order reflects Bio-Works’ continued growth and strengthens the company’s position as a strategic supplier to the global biopharmaceutical industry.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-07-2025 15:28 CET.
| Datum | 2025-07-11, kl 15:28 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!